Skip to content

BM Collection From NICU Infants for Composition

Collection and Characterization of Premature Infants Feces for Identification of Factors Contributing to Skin Irritation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02570698
Enrollment
25
Registered
2015-10-07
Start date
2015-10-31
Completion date
2017-01-23
Last updated
2017-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diaper Dermatitis

Brief summary

The primary objective of this study is to collect feces from premature infants over a five weeks period to characterize its composition. Metabolomics, Proteomics, Genomics and Microbiome analyses and cell-based assays will be performed to identify individual components present in feces, which may contribute to the onset of irritation in the diapered area of premature infants.

Interventions

None listed

Sponsors

Kimberly-Clark Corporation
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 30 Weeks
Healthy volunteers
Yes

Inclusion criteria

* Infant's parent(s)/legal guardian(s) must be fluent in English or Spanish, willing and able to read, understand, and sign the informed consent form (ICF). * Infants (male or female) who are equal or less than a gestational age of 30 weeks + 4 days.

Exclusion criteria

* Any medical condition which, in the opinion of the principal investigator, may compromise infant's safety. * Any underlying chronic skin conditions. However, infants may participate in the study with a rash in the diapered area if, in the opinion of the principal investigator, this does not compromise infant's safety.

Design outcomes

Primary

MeasureTime frameDescription
Composition of proteins (ug/uL) in premature infant feces0 to 5 weeksThis is an observational study where fecal samples will be collected twice each week for 5 weeks from enrolled patients. Primary analysis will consist of identification and quantification proteins present in samples.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026